NasdaqCM - Delayed Quote USD

Cyclacel Pharmaceuticals, Inc. (CYCC)

1.7900 +0.0400 (+2.29%)
At close: April 23 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Spiro George Rombotis President, CEO & Executive Director 612.47k -- 1959
Mr. Paul McBarron Executive VP of Finance, CFO, COO, Secretary & Executive Director 321.61k -- 1961
Ms. Gill Christie Director of Human Resources -- -- 1957
Dr. Brian Schwartz M.D. Interim Chief Medical Officer & Director 51k -- 1963
Grace Kim Investor Relations Executive -- -- --

Cyclacel Pharmaceuticals, Inc.

200 Connell Drive
Suite 1500
Berkeley Heights, NJ 07922
United States
908 517 7330 https://www.cyclacel.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Corporate Governance

Cyclacel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Cyclacel Pharmaceuticals, Inc. Earnings Call

Related Tickers

CMMB Chemomab Therapeutics Ltd.
0.6700
+1.53%
 
TRVI Trevi Therapeutics, Inc.
2.8500
-3.06%
 
FNCH Finch Therapeutics Group, Inc.
2.7888
+22.85%
 
PRTG Portage Biotech Inc.
0.2426
-19.46%
 
COEP Coeptis Therapeutics Holdings, Inc.
0.3350
-3.18%
 
SABS SAB Biotherapeutics, Inc.
4.3600
-1.13%
 
TENX Tenax Therapeutics, Inc.
3.5000
-1.41%
 
DRMA Dermata Therapeutics, Inc.
0.3397
+0.32%
 
IMNN Imunon, Inc.
1.3300
+4.72%
 
GNFT Genfit S.A.
3.4449
+0.43%